Month: May 2025

Genetic screening for Familial Hypercholesterolaemia (FH) and other inherited conditions is a cost-effective strategy that has the potential to prevent serious disease and reduce long-term healthcare costs. Despite FH affecting 1 in 250 people, most remain undiagnosed, missing opportunities for early intervention and cost-effective treatment. A health economic approach supports population-wide screening, cascade screening, and newborn screening as proactive strategies…